<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02165904</url>
  </required_header>
  <id_info>
    <org_study_id>CME-LEM2</org_study_id>
    <secondary_id>2011-005684-24</secondary_id>
    <nct_id>NCT02165904</nct_id>
  </id_info>
  <brief_title>Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in SCI</brief_title>
  <official_title>Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in Patients Suffering Incomplete Spinal Cord Injury (SCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study goes on 24 months, with recruiting, treatment and follow period for all patients.
      The first day for each patient will be the first cellular administration. 3 doses will be
      administrated every 3 months from first dose.

      When the clinical trial finishes, it will be done a completed check of all obtained
      parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a clinical trial phase I, single center, non-randomized, uncontrolled, open prospective
      follow-up of a cohort of patients with chronic spinal cord injury (SCI) .10 patients will be
      included with this injury.

      Primary objective: Analyze the possible clinical efficacy of administration of main adult
      mesenchymal autologous cells expanded &quot;in vitro&quot; in patients with incomplete and chronically
      established SCI.

      Secondary objectives: Confirm the safety of treatment, and study possible changes in the
      cerebrospinal fluid (CSF) levels (Brain-derived neurotrophic factor (BDNF), glial cell
      line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), ciliary neurotrophic
      factor (CNTF), Nerve Growth Factor 3 and 4(NT3 and NT4) after subarachnoid administration of
      BMMC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy-Sensivity Improvement Using the ASIA Score</measure>
    <time_frame>measure before treatment (baseline visit), 3, 6, 9 and 12 months after surgery</time_frame>
    <description>Sensitivity improvement was measured using the ASIA (American Spinal Injury Association) scale to measure the Surface sensitivity (LTS), pain sensitivity (PPS), and the degree of motor function in key muscles (MS). The sum of MS, LTS, and PPS configure total ASIA score. A minimum possible score is 0 points. A maximum possible score is 224 points for a patient with normal sensation. ASIA score was obtained before surgery, and 3, 6, 9 and 12 months after surgery. Mean and standard deviation for the 10 patients were obtained at all the time points and statistically analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy- Changes in Functional Independence Measure Scale</measure>
    <time_frame>measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery</time_frame>
    <description>- Changes in Functional Independence Measure scale (NIF scale), score at the beginning, through and the end of the treatment.
Ranges score: 18 to 126. Being 18 total patient dependency and 126 total patient independence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy-Change in Barthel Score</measure>
    <time_frame>measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery</time_frame>
    <description>- Changes in Barthel score at the beginning, through and the end of the treatment.
Ranges score: 0 to 100. Being 0 total patient dependency and 100 total patient independence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy-IANC-SCIFRS Scale</measure>
    <time_frame>Changes in IANC-SCIFRS scale before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)</time_frame>
    <description>-Changes in IANC-SCIFRS scale
Ranges score: 0 to 48. Being 0 severe degree of disability and 48 normal value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy-Changes in PENN Score.</measure>
    <time_frame>measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery</time_frame>
    <description>- Changes in PENN score at the beginning, through and the end of the treatment
Ranges score: 0 to 4. Being 0 absence of spasms and 4 frequency greater than 10 spasms per hour.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in ASHWORTH Score</measure>
    <time_frame>measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery</time_frame>
    <description>- Changes in ASHWORTH score at the beginning, through and the end of the treatment
Ranges score: 0 to 4. Being 0 when there isn´t increase in muscle tone when stretching, and 4 when there is rigid affected follow-up in flexion or extension</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy-Changes in EVA Score</measure>
    <time_frame>measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery</time_frame>
    <description>• Changes in EVA score at the beginning, through and the end of the treatment
Ranges score: 0 to 10. Being 0 absence of pain and 10 the worst pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy- Changes in Geffner Score</measure>
    <time_frame>Changes in Geffner scale before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)</time_frame>
    <description>changes in Geffner score before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)
Ranges score: 0 to 6. Being 0 absence of bladder control and 6 total control of bladder</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy- Changes in NBD Score</measure>
    <time_frame>measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery</time_frame>
    <description>changes in NBD score before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)
Ranges score: 0 to 47. 0-6 is very minor dysfunction. 7-9 is minor dysfunction. 10-13 is moderate dysfunction; and 14 or more is severe dysfunction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy-Changes in the Neurophysiological Parameters (SSEPs, Somatosensory Evoked Potentials)</measure>
    <time_frame>Efficacy-measure before treatment (baseline visit), 6, and 12 months after surgery</time_frame>
    <description>Changes in the neurophysiological parameters (SSEPs, somatosensory evoked potentials) measured as the number of patients that improved along the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy-Urodynammic in Terms of Detrusor Pressure</measure>
    <time_frame>Urodynamic studies before surgery, and at 6 and 12 months after surgery (follow-up</time_frame>
    <description>Urodynamic studies in terms of detrusor pressure (decrease on detrusor pressure is considered a clinical improvement)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy-Urodynamic Studies Bladder Compliance</measure>
    <time_frame>measure before treatment (baseline visit), 6 and 12 months after surgery</time_frame>
    <description>Urodynamic studies in terms of Bladder compliance. Bladder compliance is the result of a mathematical calculation of volume responsible for 1 cm H2O pressure rise measured during a cystometric filling
. It gives an indication on how the different mechanisms in the bladder wall react on stretching.
It is obvious that compliance figures can vary widely in groups which makes it difficult to define limits of normality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy-Urodynamic Studies Maximum Cystometric Capacity</measure>
    <time_frame>Urodynamic studies before surgery, and at 6 and 12 months after surgery (follow-up</time_frame>
    <description>Urodynamic studies in terms of Maximum cystometric capacity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy-modification of Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>before (baseline visit) and at 12 months</time_frame>
    <description>Number of patients with changes in morphology of injury compared with basal images</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events .</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>- The safety will be valued with number of adverse events related with administration of subarachnoid autologous Bone Marrow Expanded Mesenchymal Cells in Incomplete Spinal Cord Injury (SCI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy- Expression of Neurotrophins in CSF (CerebroSpinal Fluid) Samples</measure>
    <time_frame>Basal and 10 months after the administration</time_frame>
    <description>Changes in expression of neurotrophins in CSF (CerebroSpinal Fluid) samples obtained previously to first administration of cell therapy, and previously to the last administration, at month 10, in order to study the variability in the expression of neurotrophins along time. The mean+SD (standard deviation) at each time point was obtained. The tested neurotrophins were: BDNF.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Autologous Mesenchymal Bone Marrow Cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow Cell</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adult Autologous Mesenchymal Bone Marrow Cell</intervention_name>
    <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.</description>
    <arm_group_label>Autologous Mesenchymal Bone Marrow Cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Incomplete SCI

          2. Neurological deficit clinically stable at least 12 months prior to treatment, and with
             a minimum of one-year evolution after SCI.

          3. Neurophysiological confirmation of incomplete SCI.

          4. The MRI study that morphologically evaluate the SCI.

          5. Age between 18 and 70 years

          6. Thread Men and women will compromise to use anticonceptive issues from first cell´s
             extraction to 6 months after last cell´s administration.

          7. Ability to attend clinical follow-up and perform physical therapy through the
             treatment period.

          8. Written and signed informed consent, according to the local regulation.

          9. Hematologic and creatinin parameters, SGOT and SGPT, within the normal range,
             according to laboratory standards considering that small variations could be accepted
             based on clinical study team criteria.

        Exclusion Criteria:

          1. A classification in ASIA and FRANKEL clinical scales to evaluate the SCI.

          2. Neurophysiological records that confirm the complete SCI.

          3. Age below 18 years or above 70.

          4. Pregnancy or lactation.

          5. Malignancy disease diagnosed or treated within the last 5 years.

          6. Patients with systemic disease that represents and additional risk to treatment.

          7. Patients with uncertain commitment to follow the physical therapy and clinical visits
             as well as patient with a negative input in the previous phycological assessment.

          8. Inability to assess the SCI features through MRI either noise due to spinal
             stabilization systems or any other cause.

          9. Patients currently under hematopoietic growth factors treatment or who required or
             maintained anticoagulation.

         10. Neurodegenerative disease additional.

         11. History of substance abuse, psychiatric disease or allergy to the protein products
             used in the process of cell expansion.

         12. Positive serology for HIV and syphilis.

         13. Active Hepatitis B or Hepatitis C.

         14. With other reason that would consider the patient ineligible for cell therapy
             according to the investigators judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesús JV Vaquero Crespo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta de Hierro-Majadahonda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Vaquero J, Zurita M. Functional recovery after severe CNS trauma: current perspectives for cell therapy with bone marrow stromal cells. Prog Neurobiol. 2011 Mar;93(3):341-9. doi: 10.1016/j.pneurobio.2010.12.002. Epub 2010 Dec 14. Review.</citation>
    <PMID>21163325</PMID>
  </reference>
  <reference>
    <citation>Otero L, Zurita M, Bonilla C, Aguayo C, Vela A, Rico MA, Vaquero J. Late transplantation of allogeneic bone marrow stromal cells improves neurologic deficits subsequent to intracerebral hemorrhage. Cytotherapy. 2011 May;13(5):562-71. doi: 10.3109/14653249.2010.544720. Epub 2011 Jan 5.</citation>
    <PMID>21208021</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <results_first_submitted>September 3, 2018</results_first_submitted>
  <results_first_submitted_qc>May 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 19, 2019</results_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>Jesús Vaquero Crespo, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Analyze clinical efficacy of subarachnoid administration of</keyword>
  <keyword>autologous BMSC expanded &quot;in vitro&quot;</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual data of participants will be shared with Authorities at the end of the Clinical development plan by the CTD (Common Technical Document). Results will be published in a scientific publication</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Autologous Mesenchymal Bone Marrow Cell</title>
          <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Autologous Mesenchymal Bone Marrow Cell</title>
          <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy-Sensivity Improvement Using the ASIA Score</title>
        <description>Sensitivity improvement was measured using the ASIA (American Spinal Injury Association) scale to measure the Surface sensitivity (LTS), pain sensitivity (PPS), and the degree of motor function in key muscles (MS). The sum of MS, LTS, and PPS configure total ASIA score. A minimum possible score is 0 points. A maximum possible score is 224 points for a patient with normal sensation. ASIA score was obtained before surgery, and 3, 6, 9 and 12 months after surgery. Mean and standard deviation for the 10 patients were obtained at all the time points and statistically analyzed.</description>
        <time_frame>measure before treatment (baseline visit), 3, 6, 9 and 12 months after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy-Sensivity Improvement Using the ASIA Score</title>
          <description>Sensitivity improvement was measured using the ASIA (American Spinal Injury Association) scale to measure the Surface sensitivity (LTS), pain sensitivity (PPS), and the degree of motor function in key muscles (MS). The sum of MS, LTS, and PPS configure total ASIA score. A minimum possible score is 0 points. A maximum possible score is 224 points for a patient with normal sensation. ASIA score was obtained before surgery, and 3, 6, 9 and 12 months after surgery. Mean and standard deviation for the 10 patients were obtained at all the time points and statistically analyzed.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.2" spread="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.2" spread="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.4" spread="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.9" spread="51.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235.5" spread="49.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy- Changes in Functional Independence Measure Scale</title>
        <description>- Changes in Functional Independence Measure scale (NIF scale), score at the beginning, through and the end of the treatment.
Ranges score: 18 to 126. Being 18 total patient dependency and 126 total patient independence.</description>
        <time_frame>measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy- Changes in Functional Independence Measure Scale</title>
          <description>- Changes in Functional Independence Measure scale (NIF scale), score at the beginning, through and the end of the treatment.
Ranges score: 18 to 126. Being 18 total patient dependency and 126 total patient independence.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" spread="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" spread="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" spread="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.10" spread="33.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" spread="32.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy-Change in Barthel Score</title>
        <description>- Changes in Barthel score at the beginning, through and the end of the treatment.
Ranges score: 0 to 100. Being 0 total patient dependency and 100 total patient independence.</description>
        <time_frame>measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy-Change in Barthel Score</title>
          <description>- Changes in Barthel score at the beginning, through and the end of the treatment.
Ranges score: 0 to 100. Being 0 total patient dependency and 100 total patient independence.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="36.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="36.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="36.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="36.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" spread="35.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy-IANC-SCIFRS Scale</title>
        <description>-Changes in IANC-SCIFRS scale
Ranges score: 0 to 48. Being 0 severe degree of disability and 48 normal value.</description>
        <time_frame>Changes in IANC-SCIFRS scale before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy-IANC-SCIFRS Scale</title>
          <description>-Changes in IANC-SCIFRS scale
Ranges score: 0 to 48. Being 0 severe degree of disability and 48 normal value.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.10" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.90" spread="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy-Changes in PENN Score.</title>
        <description>- Changes in PENN score at the beginning, through and the end of the treatment
Ranges score: 0 to 4. Being 0 absence of spasms and 4 frequency greater than 10 spasms per hour.</description>
        <time_frame>measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy-Changes in PENN Score.</title>
          <description>- Changes in PENN score at the beginning, through and the end of the treatment
Ranges score: 0 to 4. Being 0 absence of spasms and 4 frequency greater than 10 spasms per hour.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in ASHWORTH Score</title>
        <description>- Changes in ASHWORTH score at the beginning, through and the end of the treatment
Ranges score: 0 to 4. Being 0 when there isn´t increase in muscle tone when stretching, and 4 when there is rigid affected follow-up in flexion or extension</description>
        <time_frame>measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in ASHWORTH Score</title>
          <description>- Changes in ASHWORTH score at the beginning, through and the end of the treatment
Ranges score: 0 to 4. Being 0 when there isn´t increase in muscle tone when stretching, and 4 when there is rigid affected follow-up in flexion or extension</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy-Changes in EVA Score</title>
        <description>• Changes in EVA score at the beginning, through and the end of the treatment
Ranges score: 0 to 10. Being 0 absence of pain and 10 the worst pain.</description>
        <time_frame>measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy-Changes in EVA Score</title>
          <description>• Changes in EVA score at the beginning, through and the end of the treatment
Ranges score: 0 to 10. Being 0 absence of pain and 10 the worst pain.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy- Changes in Geffner Score</title>
        <description>changes in Geffner score before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)
Ranges score: 0 to 6. Being 0 absence of bladder control and 6 total control of bladder</description>
        <time_frame>Changes in Geffner scale before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy- Changes in Geffner Score</title>
          <description>changes in Geffner score before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)
Ranges score: 0 to 6. Being 0 absence of bladder control and 6 total control of bladder</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy- Changes in NBD Score</title>
        <description>changes in NBD score before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)
Ranges score: 0 to 47. 0-6 is very minor dysfunction. 7-9 is minor dysfunction. 10-13 is moderate dysfunction; and 14 or more is severe dysfunction.</description>
        <time_frame>measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy- Changes in NBD Score</title>
          <description>changes in NBD score before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)
Ranges score: 0 to 47. 0-6 is very minor dysfunction. 7-9 is minor dysfunction. 10-13 is moderate dysfunction; and 14 or more is severe dysfunction.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.60" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.10" spread="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.70" spread="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" spread="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy-Changes in the Neurophysiological Parameters (SSEPs, Somatosensory Evoked Potentials)</title>
        <description>Changes in the neurophysiological parameters (SSEPs, somatosensory evoked potentials) measured as the number of patients that improved along the study.</description>
        <time_frame>Efficacy-measure before treatment (baseline visit), 6, and 12 months after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy-Changes in the Neurophysiological Parameters (SSEPs, Somatosensory Evoked Potentials)</title>
          <description>Changes in the neurophysiological parameters (SSEPs, somatosensory evoked potentials) measured as the number of patients that improved along the study.</description>
          <units>number of patients improved in SSEPs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy-Urodynammic in Terms of Detrusor Pressure</title>
        <description>Urodynamic studies in terms of detrusor pressure (decrease on detrusor pressure is considered a clinical improvement)</description>
        <time_frame>Urodynamic studies before surgery, and at 6 and 12 months after surgery (follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy-Urodynammic in Terms of Detrusor Pressure</title>
          <description>Urodynamic studies in terms of detrusor pressure (decrease on detrusor pressure is considered a clinical improvement)</description>
          <units>cm/H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" spread="20.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" spread="37.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy-Urodynamic Studies Bladder Compliance</title>
        <description>Urodynamic studies in terms of Bladder compliance. Bladder compliance is the result of a mathematical calculation of volume responsible for 1 cm H2O pressure rise measured during a cystometric filling
. It gives an indication on how the different mechanisms in the bladder wall react on stretching.
It is obvious that compliance figures can vary widely in groups which makes it difficult to define limits of normality.</description>
        <time_frame>measure before treatment (baseline visit), 6 and 12 months after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy-Urodynamic Studies Bladder Compliance</title>
          <description>Urodynamic studies in terms of Bladder compliance. Bladder compliance is the result of a mathematical calculation of volume responsible for 1 cm H2O pressure rise measured during a cystometric filling
. It gives an indication on how the different mechanisms in the bladder wall react on stretching.
It is obvious that compliance figures can vary widely in groups which makes it difficult to define limits of normality.</description>
          <units>mL/cm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.14" spread="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.28" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy-Urodynamic Studies Maximum Cystometric Capacity</title>
        <description>Urodynamic studies in terms of Maximum cystometric capacity</description>
        <time_frame>Urodynamic studies before surgery, and at 6 and 12 months after surgery (follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy-Urodynamic Studies Maximum Cystometric Capacity</title>
          <description>Urodynamic studies in terms of Maximum cystometric capacity</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.9" spread="156.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292.4" spread="110.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292.6" spread="183.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy-modification of Magnetic Resonance Imaging (MRI)</title>
        <description>Number of patients with changes in morphology of injury compared with basal images</description>
        <time_frame>before (baseline visit) and at 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy-modification of Magnetic Resonance Imaging (MRI)</title>
          <description>Number of patients with changes in morphology of injury compared with basal images</description>
          <units>number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events .</title>
        <description>- The safety will be valued with number of adverse events related with administration of subarachnoid autologous Bone Marrow Expanded Mesenchymal Cells in Incomplete Spinal Cord Injury (SCI).</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events .</title>
          <description>- The safety will be valued with number of adverse events related with administration of subarachnoid autologous Bone Marrow Expanded Mesenchymal Cells in Incomplete Spinal Cord Injury (SCI).</description>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy- Expression of Neurotrophins in CSF (CerebroSpinal Fluid) Samples</title>
        <description>Changes in expression of neurotrophins in CSF (CerebroSpinal Fluid) samples obtained previously to first administration of cell therapy, and previously to the last administration, at month 10, in order to study the variability in the expression of neurotrophins along time. The mean+SD (standard deviation) at each time point was obtained. The tested neurotrophins were: BDNF.</description>
        <time_frame>Basal and 10 months after the administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Mesenchymal Bone Marrow Cell</title>
            <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy- Expression of Neurotrophins in CSF (CerebroSpinal Fluid) Samples</title>
          <description>Changes in expression of neurotrophins in CSF (CerebroSpinal Fluid) samples obtained previously to first administration of cell therapy, and previously to the last administration, at month 10, in order to study the variability in the expression of neurotrophins along time. The mean+SD (standard deviation) at each time point was obtained. The tested neurotrophins were: BDNF.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BDNF before administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.14" spread="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BDNF in month 10 after administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.82" spread="49.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Autologous Mesenchymal Bone Marrow Cell</title>
          <description>Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Acute Bronchitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Local pain</sub_title>
                <description>Local pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <description>Hyperthermia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Urinary tract infection</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infected pressure ulcer</sub_title>
                <description>Infected pressure ulcer</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasopharingytis</sub_title>
                <description>Nasopharingytis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Bronchitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <description>Wound</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg pain</sub_title>
                <description>Leg pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Arthralgia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <description>Neck pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Back pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Syncope</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain in coccyx</sub_title>
                <description>Pain in coccyx</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <description>Urinary retention</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Hypertension</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Vaquero Crespo</name_or_title>
      <organization>Hospital Universitario Puerta de Hierro Majadahonda, Madrid</organization>
      <phone>91 191 7760</phone>
      <email>jesus.vaquero@salud.madrid.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

